熱門資訊> 正文
Skye在Evercore因肥胖资产nimacimab而发起超重
2025-08-15 21:43
- Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE) due to its development of the CB1 inhibitor nimacimab for obesity.
- The firm has a $10 price target (~206% upside based on Thursday's close).
- Analyst Michael DiFiore believes that as a CB1 inhibitor, nimacimab would differentiate itself from the GLP-1s from Novo Nordisk (NVO) and Eli Lilly (LLY) that are dominating the market.
- He noted that the candidate could fill gaps in obesity care in several ways: as a GLP-1 off-ramp/maintenance option; as a combo therapy in severe obesity; and as a non-incretin monotherapy for some patients.
- DiFiore added that the newest generation of CB1 inhibitors appears to avoid the central nervous issues that plagued earlier generations.
- Looking ahead, he sees the next major catalyst for nimacimab coming in late Q3 or early Q4 with phase 2a data.
More on Skye Bioscience
- Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript
- Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing
- Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform
- Skye Bioscience GAAP EPS of -$0.44 misses by $0.13
- Seeking Alpha’s Quant Rating on Skye Bioscience
推薦文章
一周財經日曆丨降息信號將定？下周全球央行年會成關鍵；小米、泡泡瑪特、快手領銜港股財報潮
港股周報丨見證歷史！南向資金單日瘋狂買入港股359億港元；騰訊績后股價一度升破600港元
特朗普政府據悉考慮動用芯片法案資金來入股英特爾
美股機會日報丨「恐怖數據」符合預期，交易員下調美聯儲降息預期；巴菲特Q2新建倉股飆升，聯合健康盤前漲超10%
銀諾醫藥-B上市首日暴漲285%，一手賺超1萬港元
投資大佬Tepper減持阿里巴巴、京東等 買入股價暴跌的聯合健康
伯克希爾減持蘋果股份 增持聯合健康集團
8月15日外盤頭條：特朗普政府洽購英特爾股份 貝森特否認推動降息 蘋果重新設計Apple Watch血氧功能
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
